ES2186153T3 - Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. - Google Patents
Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.Info
- Publication number
- ES2186153T3 ES2186153T3 ES98918789T ES98918789T ES2186153T3 ES 2186153 T3 ES2186153 T3 ES 2186153T3 ES 98918789 T ES98918789 T ES 98918789T ES 98918789 T ES98918789 T ES 98918789T ES 2186153 T3 ES2186153 T3 ES 2186153T3
- Authority
- ES
- Spain
- Prior art keywords
- pregnan
- sulfate
- ona
- alfa
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- AURFZBICLPNKBZ-FZCSVUEKSA-N 3beta-hydroxy-5alpha-pregnan-20-one Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-FZCSVUEKSA-N 0.000 abstract 1
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001072 progestational effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La invención suministra un procedimiento para suministrar terapia progestacional a un mamífero que tenga necesidad de la misma, el procedimiento comprende la administración de una cantidad progestacionalmente efectiva de una sal farmacológicamente aceptable de 5-alfa-pregnan-3beta-ol-20-ona 3-sulfato éster a dicho mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85056797A | 1997-05-02 | 1997-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2186153T3 true ES2186153T3 (es) | 2003-05-01 |
Family
ID=25308504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98918789T Expired - Lifetime ES2186153T3 (es) | 1997-05-02 | 1998-04-28 | Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0981349B1 (es) |
| JP (1) | JP2001525807A (es) |
| KR (1) | KR20010012157A (es) |
| CN (1) | CN1254283A (es) |
| AR (1) | AR012638A1 (es) |
| AT (1) | ATE227130T1 (es) |
| AU (1) | AU739146B2 (es) |
| BR (1) | BR9809376A (es) |
| CA (1) | CA2289006A1 (es) |
| DE (1) | DE69809223T2 (es) |
| DK (1) | DK0981349T3 (es) |
| ES (1) | ES2186153T3 (es) |
| PT (1) | PT981349E (es) |
| WO (1) | WO1998050042A1 (es) |
| ZA (1) | ZA983705B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1270718C (zh) * | 1998-03-11 | 2006-08-23 | 托布乔恩·贝克斯托罗姆 | 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用 |
| SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Umecrine Ab | Pregnane steroids and their use in the treatment of CNS disorders |
| US7572780B2 (en) | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
| US7473687B2 (en) | 2005-03-24 | 2009-01-06 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| US20090325920A1 (en) | 2005-03-24 | 2009-12-31 | Emory University | Methods for the treatment of a traumatic central nervous system injury |
| WO2006117592A1 (en) * | 2005-04-29 | 2006-11-09 | Inserm | Methods of modulating nuclear receptors |
| HUE027298T2 (en) | 2010-01-14 | 2016-10-28 | Asarina Pharma Ab | Pharmaceutical composition containing developed storage and dissolution properties containing 3-beta-hydroxy-5-alpha-pregnan-20-one |
-
1998
- 1998-04-28 WO PCT/US1998/008456 patent/WO1998050042A1/en not_active Ceased
- 1998-04-28 AT AT98918789T patent/ATE227130T1/de not_active IP Right Cessation
- 1998-04-28 ES ES98918789T patent/ES2186153T3/es not_active Expired - Lifetime
- 1998-04-28 BR BR9809376-2A patent/BR9809376A/pt not_active IP Right Cessation
- 1998-04-28 EP EP98918789A patent/EP0981349B1/en not_active Expired - Lifetime
- 1998-04-28 DK DK98918789T patent/DK0981349T3/da active
- 1998-04-28 PT PT98918789T patent/PT981349E/pt unknown
- 1998-04-28 KR KR19997010102A patent/KR20010012157A/ko not_active Withdrawn
- 1998-04-28 DE DE69809223T patent/DE69809223T2/de not_active Expired - Fee Related
- 1998-04-28 CA CA002289006A patent/CA2289006A1/en not_active Abandoned
- 1998-04-28 AU AU71647/98A patent/AU739146B2/en not_active Ceased
- 1998-04-28 CN CN98804719A patent/CN1254283A/zh active Pending
- 1998-04-28 JP JP54815598A patent/JP2001525807A/ja active Pending
- 1998-04-30 AR ARP980102025A patent/AR012638A1/es unknown
- 1998-04-30 ZA ZA9803705A patent/ZA983705B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK0981349T3 (da) | 2003-03-10 |
| EP0981349A1 (en) | 2000-03-01 |
| PT981349E (pt) | 2003-01-31 |
| CN1254283A (zh) | 2000-05-24 |
| CA2289006A1 (en) | 1998-11-12 |
| JP2001525807A (ja) | 2001-12-11 |
| AU739146B2 (en) | 2001-10-04 |
| BR9809376A (pt) | 2000-07-04 |
| EP0981349B1 (en) | 2002-11-06 |
| ZA983705B (en) | 1999-11-01 |
| ATE227130T1 (de) | 2002-11-15 |
| AU7164798A (en) | 1998-11-27 |
| KR20010012157A (ko) | 2001-02-15 |
| AR012638A1 (es) | 2000-11-08 |
| DE69809223D1 (de) | 2002-12-12 |
| DE69809223T2 (de) | 2003-07-24 |
| WO1998050042A1 (en) | 1998-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| DE69434211D1 (de) | Phenylacetate und derivate, allein oder in kombination mit anderen verbindungen, zur behandlung von neoplastischen und anderen erkrankungen | |
| ES2150663T3 (es) | Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina. | |
| UY26693A1 (es) | Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero | |
| CL2008003938A1 (es) | Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00). | |
| BG105534A (en) | 5ht1 means and method for the treatment of migraine | |
| MY119375A (en) | Treatment of tinnitus using neuroprotective agents | |
| MX9302038A (es) | Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s. | |
| PA8467401A1 (es) | Procedimiento para tratar la insuficiencia cardiaca | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| NO20003313D0 (no) | Terapeutiske midler | |
| EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
| ES2186153T3 (es) | Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. | |
| CO5160295A1 (es) | Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri | |
| FR2767526B1 (fr) | Composes bi-aromatiques relies par un radical heteroethynylene et compositions pharmaceutiques et cosmetiques les contenant | |
| DK0799618T3 (da) | Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer | |
| AR002191A1 (es) | Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion | |
| PT1019068E (pt) | Formulações terapêuticas contendo veneno de serpente e/ou insecto para a profilaxia e terapia de neoplasmas | |
| ES2182524T3 (es) | Composiciones de hidroxiomeprazol y sus utilizaciones. | |
| AR022348A1 (es) | Una composicion farmaceutica para el tratamiento de los sintomas del tracto urinario inferior | |
| AR023464A1 (es) | Usos novedosos de la proteina ox2 de mamifero y reactivos relacionados | |
| BR0012121A (pt) | Derivado de aminotetralina para terapia de doenças cardiovasculares | |
| AR018321A1 (es) | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. | |
| PA8480401A1 (es) | Un metodo para la prevencion del inicio del asma | |
| AR005866A1 (es) | Composicion farmaceutica antioxidante |